139 related articles for article (PubMed ID: 17698328)
21. Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.
Guo HL; Wu DD; Fu D; Li Y; Wang J; Zhang YY; Wang WJ; Huang J; Fang WR; Xu J; Hu YH; Liu QQ; Chen F
Transl Psychiatry; 2024 Mar; 14(1):151. PubMed ID: 38504095
[TBL] [Abstract][Full Text] [Related]
22. Academic outcomes in Asian children aged 8-11 years with attention-deficit/hyperactivity disorder treated with atomoxetine hydrochloride.
Mendez L; Singh P; Harrison G; Huang YS; Jin X; Cho SC
Int J Psychiatry Clin Pract; 2011 Jun; 15(2):145-56. PubMed ID: 22121863
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.
Buitelaar JK; Michelson D; Danckaerts M; Gillberg C; Spencer TJ; Zuddas A; Faries DE; Zhang S; Biederman J
Biol Psychiatry; 2007 Mar; 61(5):694-9. PubMed ID: 16893523
[TBL] [Abstract][Full Text] [Related]
24. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing.
Block SL; Kelsey D; Coury D; Lewis D; Quintana H; Sutton V; Schuh K; Allen AJ; Sumner C
Clin Pediatr (Phila); 2009 Sep; 48(7):723-33. PubMed ID: 19420182
[TBL] [Abstract][Full Text] [Related]
25. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
[TBL] [Abstract][Full Text] [Related]
26. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
Spencer TJ; Sallee FR; Gilbert DL; Dunn DW; McCracken JT; Coffey BJ; Budman CL; Ricardi RK; Leonard HL; Allen AJ; Milton DR; Feldman PD; Kelsey DK; Geller DA; Linder SL; Lewis DW; Winner PK; Kurlan RM; Mintz M
J Atten Disord; 2008 Jan; 11(4):470-81. PubMed ID: 17934184
[TBL] [Abstract][Full Text] [Related]
27. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.
Adler LA; Spencer TJ; Williams DW; Moore RJ; Michelson D
J Atten Disord; 2008 Nov; 12(3):248-53. PubMed ID: 18448861
[TBL] [Abstract][Full Text] [Related]
28. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
29. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
[TBL] [Abstract][Full Text] [Related]
30. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning.
Brown RT; Perwien A; Faries DE; Kratochvil CJ; Vaughan BS
Clin Pediatr (Phila); 2006 Nov; 45(9):819-27. PubMed ID: 17041169
[TBL] [Abstract][Full Text] [Related]
31. [Drugs for attention deficit hyperactivity disorder].
Montañés-Rada F; Gangoso-Fermoso AB; Martíínez-Granero MA
Rev Neurol; 2009 May 1-15; 48(9):469-81. PubMed ID: 19396764
[TBL] [Abstract][Full Text] [Related]
32. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
Niederhofer H
Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
[No Abstract] [Full Text] [Related]
33. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
34. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Brown JT; Bishop JR; Sangkuhl K; Nurmi EL; Mueller DJ; Dinh JC; Gaedigk A; Klein TE; Caudle KE; McCracken JT; de Leon J; Leeder JS
Clin Pharmacol Ther; 2019 Jul; 106(1):94-102. PubMed ID: 30801677
[TBL] [Abstract][Full Text] [Related]
35. Decreased use of clonidine following treatment with atomoxetine in children with ADHD.
Johnston JA; Ye W; Van Brunt DL; Pohl G; Sumner CR
J Clin Psychopharmacol; 2006 Aug; 26(4):389-95. PubMed ID: 16855457
[TBL] [Abstract][Full Text] [Related]
36. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.
Buitelaar JK; Wilens TE; Zhang S; Ning Y; Feldman PD
J Child Psychol Psychiatry; 2009 Mar; 50(3):335-42. PubMed ID: 19309330
[TBL] [Abstract][Full Text] [Related]
37. Combined overdose of atomoxetine and methylphenidate in a cytochrome P450 2D6 poor metabolizer.
Reimers A; Langsetmo HK
J Clin Psychopharmacol; 2007 Feb; 27(1):110-1. PubMed ID: 17224704
[No Abstract] [Full Text] [Related]
38. Clinical pharmacokinetics of atomoxetine.
Sauer JM; Ring BJ; Witcher JW
Clin Pharmacokinet; 2005; 44(6):571-90. PubMed ID: 15910008
[TBL] [Abstract][Full Text] [Related]
39. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
[TBL] [Abstract][Full Text] [Related]
40. An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6.
Bonnet-Brilhault F; Broly F; Blanc R; Furet Y; Barthélémy C; Paintaud G
J Clin Psychopharmacol; 2006 Aug; 26(4):442-4. PubMed ID: 16855474
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
